References

1   Li, W., Choe, H. & Farzan, M. Insights from the association of SARS-CoV S-protein with its receptor, ACE2. *Advances in experimental medicine and biology* **581**, 209-218, doi:10.1007/978-0-387-33012-9_36 (2006).

2   Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* **1282**, 1-23, doi:10.1007/978-1-4939-2438-7_1 (2015).

3   Shang, J. *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221-224, doi:10.1038/s41586-020-2179-y (2020).

4   Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).

5   Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, doi:10.1016/j.cell.2020.02.058 (2020).

6   Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).

7   Wang, Q. *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **181**, 894-904 e899, doi:10.1016/j.cell.2020.03.045 (2020).

8   Li, W. *et al.* Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **426**, 450-454, doi:10.1038/nature02145 (2003).

9   Li, W. *et al.* Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J* **24**, 1634-1643, doi:10.1038/sj.emboj.7600640 (2005).

10   Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *The Journal of biological chemistry* **279**, 3197-3201, doi:10.1074/jbc.C300520200 (2004).

11   Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science* **309**, 1864-1868, doi:10.1126/science.1116480 (2005).

12   Shang, J. *et al.* Cell entry mechanisms of SARS-CoV-2. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 11727-11734, doi:10.1073/pnas.2003138117 (2020).

13   Glowacka, I. *et al.* Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *Journal of virology* **85**, 4122-4134, doi:10.1128/JVI.02232-10 (2011).

14   Huang, I. C. *et al.* SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. *The Journal of biological chemistry* **281**, 3198-3203, doi:10.1074/jbc.M508381200 (2006).

15   Matsuyama, S. *et al.* Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease

TMPRSS2. *Journal of virology* **84**, 12658-12664, doi:10.1128/JVI.01542-10 (2010).

16   Millet, J. K. & Whittaker, G. R. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. *Virus research* **202**, 120-134, doi:10.1016/j.virusres.2014.11.021 (2015).

17   Shulla, A. *et al.* A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. *Journal of virology* **85**, 873-882, doi:10.1128/JVI.02062-10 (2011).

18   Simmons, G. *et al.* Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 11876-11881, doi:10.1073/pnas.0505577102 (2005).

19   Belouzard, S., Chu, V. C. & Whittaker, G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 5871-5876, doi:10.1073/pnas.0809524106 (2009).

20   Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, doi:10.1016/j.cell.2020.02.052 (2020).

21   Júnior, I. J. M., Polveiro, R. C., Souza, G. M., Inserra, D. & Bortolin, F. T. S., Alison Talis Martins Lima. The global population of SARS-CoV-2 is composed of six major subtypes. *bioRxiv* (2020).

22   Korber, B. *et al.* Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. *bioRxiv* (2020).

23   Laha, S. *et al.* Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. *bioRxiv* (2020).

24   LAAMARTI, M. *et al.* Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations. *bioRxiv*.

25   Lokman, S. M. *et al.* Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: a computational biology approach. *bioRxiv* (2020).

26   Comandatore, F. *et al.* Insurgence and worldwide diffusion of genomic variants in SARS-CoV-2 genomes. *bioRxiv* (2020).

27   Zhang, L. *et al.* Genome-wide variations of 1 SARS-CoV-2 infer evolution relationship and transmission route. *bioRxiv* (2020).

28   van Dorp, L. *et al.* No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *bioRxiv* (2020).

29   Bhowmik, D., Pal, S., Lahiri, A., Talukdar, A. & Paul, S. Emergence of multiple variants of SARS-CoV-2 with signature structural changes. *bioRxiv* (2020).

30   Cortey, M. *et al.* SARS-CoV-2 amino acid substitutions widely spread in the human population are mainly located in highly conserved segments of the structural proteins. *bioRxiv* (2020).

31   Moore, M. J. *et al.* Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. *Journal of virology* **78**, 10628-10635, doi:10.1128/JVI.78.19.10628-10635.2004 (2004).

32 Ou, X. *et al.* Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* **11**, 1620, doi:10.1038/s41467-020-15562-9 (2020).

33 Slootstra, J. W., Kuperus, D., Pluckthun, A. & Meloen, R. H. Identification of new tag sequences with differential and selective recognition properties for the anti-FLAG monoclonal antibodies M1, M2 and M5. *Mol Divers* **2**, 156-164, doi:10.1007/BF01682203 (1997).

34 Huang, Y., Yang, Z. Y., Kong, W. P. & Nabel, G. J. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. *Journal of virology* **78**, 12557-12565, doi:10.1128/JVI.78.22.12557-12565.2004 (2004).

35 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).